Arun Menawat, CEO of Profound Medical (NASDAQ:PROF; TSX:PRN), was one of three nominees for the 2020 Bloom Burton award, which honors an individual who has made the most significant contribution to Canada’s innovative...
The incidence of prostate cancer among adolescents and young adults has increased in the U.S. and many other countries during the past three decades, in direct contrast to older men, according to study results published...
Raymond James initiated coverage of Profound Medical (TSX:PRN; OTCQX:PRFMF) with an “outperform” rating and price target of $4. The stock closed at 92 cents on Aug. 23. “With its highly experienced management team...
Profound Medical (TSX:PRN; OTCQX:PRFMF) received FDA clearance to market TULSA-PRO for the ablation of prostate tissue, with an FDA label allowing U.S. surgeons to perform procedures on both malignant and benign tissue...
Steve Forte Profound Medical (TSX:PRN; OTCQX:PRFMF) appointed seasoned cross-border finance leader, Steve Forte, as a director and member of the board’s audit committee. Most recently, Mr. Forte was CFO of Clementia...
Profound Medical (TSXV:PRN; OTCQX:PRFMF) appointed Ian Heynen as SVP of sales and marketing. Mr. Heynen brings to Profound more than 15 years of progressive leadership experience, working with medical device companies...